Concerns are growing about the future of the Roche pharmaceutical plant at Clarecastle, in Co Clare.
This follows a decision by the company not to produce a new cholesterol drug at the Clarecastle plant and whether this has implications for jobs.
Roche employs 300 people at the plant,and has been there since 1974.
The staff at the plant have been informed by senior management that the parent company, based in Basel in Switzerland, is assessing the impact of the decision not to produce the drug Dalcetrapib on the Clare site.
This process is nearing completion and once it has been achieved, the outcome of the review will be shared with employees, a company statement said.
It is expected that a decision will be made next week.
Meanwhile, the Abbott healthcare company is seeking 29 voluntary redundancies from its staff at its Finisklin plant in Sligo.
400 people are employed in the diagnostics facility but the company says there is over-capacity in the manufacturing area where a product is being retired from the market and the next generation of solutions is being developed for sale within the next few years.
Abbott Diagnostics say they are offering a competitive package and outplacement services including assistance with training. Abbott employs almost 4,000 people in 13 sites in eight counties. It says the announcement regarding the Finisklin plant in Sligo does not impact on any of its other sites.
